February
16
TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies
Data Further Supports the Potential of the Company’s Therapeutic Platform to Improve Immunotherapy Outcomes...